Thomas Gad - Sep 2, 2021 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Chairman, President and Head of Business Development & Strategy, Director
Signature
/s/ THOMAS GAD
Stock symbol
YMAB
Transactions as of
Sep 2, 2021
Transactions value $
-$1,558,915
Form type
4
Date filed
9/7/2021, 05:30 PM
Previous filing
Aug 17, 2021
Next filing
Sep 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Sale -$1.66M -50K -3.22% $33.18* 1.5M Sep 2, 2021 By GAD Enterprises LLC F1, F2
transaction YMAB Common Stock Options Exercise $100K +50K $2.00 50K Sep 7, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Options Exercise $0 -50K -18.59% $0.00 219K Sep 7, 2021 Common Stock 50K $2.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $33.10 to $33.74. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
F3 The stock option vested and became exercisable as to 25% of the shares subject to the option on June 10, 2016, and thereafter vested as to 1/48th of the shares in equal monthly installments, until such time as the option was 100% vested on June 10, 2019.

Remarks:

Chairman, President and Head of Business Development & Strategy